Director of Ventures

Schrödinger have been awarded $19.5m by the Bill & Melinda Gates Foundation to use their platform to accelerate drug discovery for neglected diseases.

New Methods For Drug DiscoveryDiscovering new drugs has become increasingly expensive and complex in the last few decades, with new therapies costing more than a billion dollars to be developed.This is partly because all the low-hanging fruits are already picked, like known medicinal plants and “easy” to find biochemicals.Another factor is that the diseases yet to find an efficient treatment for are the most complex ones, often caused by a body complex dysfunction (diabetes, Alzheimer's, cancer, obesity, etc.) or hard-to-reach causes (for example parasites and viruses like HIV or malaria, very good at evading the immune system).This means that for discovering new molecules now, hundreds of thousands or even millions of compounds must be considered before narrowing it down to a few.This is a daunting task, and an expensive process as well.Luckily, progress in AI and computation has made it possible to comb through astronomical volume of data, at a much lower cost in both dollars and time.And two companies are now merging to speed up the adoption of AI-driven drug discovery.Exscientia Recursion MergerOn August 8th, 2024  the merger of Exscientia with its larger peer Recursion Pharmaceuticals was announced.Both companies had developed their own process to leverage AI and automation to speed up drug discovery, as well as reduce costs.A strong argument for the merger is that both companies' technologies are quite complementary. We will look in detail below at both companies, but the overall picture is such:Recursion is focused on “first-in-disease” opportunities, through a deeper understanding of biological mechanisms.Exscientia is focused on “best-in-class” drugs, with expertise in precision chemistry and molecular synthesis.So together, the combined company not only gets some additional scale to save money on overhead costs and regulatory compliance (usually the goal of mergers in biotech) but also the combination of excellence in chemistry synthesis AND biological insights.Exscientia The company is using AI to develop precision therapies.It runs a “full stack” AI drug discovery technology with dedicated software at every stage of the drug discovery process.So instead of looking at existing molecules, Exscientia’s Precision Design AI designs custom molecules to match the target found by its Precision Target AI.Exscientia's technology reduces 70% of the time required for going from a biological target to finding a corresponding drug and an 80% more capital-efficient process.Part of the time and cost saving comes from a highly automatized process, with “comprehensive robotic automation across the entire experimentation cycle”.This resulted in 4 compounds in early clinical stages, 30 programs in total, and $6.5B in revenues from milestones with partners. The main focus has been oncology (cancer) and inflammatory diseases.Recursion Pharma Recursion Pharmaceuticals leverages AI in drug discovery. The more AIs get involved in drug discovery and development, the more data will become precious for training the AIs.Biology is an extremely complex field, with integrated and verified data sometimes in short supply. This is a serious problem when any error will create bias, limitations, and errors in the AI, which might then need to be retrained from scratch.So creating solid datasets has been the focus of the company since its inception looking to solve several problems with biodata:Analog data, from faxes to pdf or scanned printouts.Siloed data, with little to no annotations.Hard to replicate research.To solve these problems, Recursion created one of the world's largest automated wet labs, and digitized millions of their own experiments (2.2 million experiments per week).It combines dry lab (in-silico) and wet lab (biological samples) with:A library of 1.7 million small molecules.Cell cultures, CRISPR gene editing, soluble factors, live viruses, etc.An automated laboratory robotics workflow that allows for up to 2.2 million experiments each week.High-throughput microscopes and sequencing systems.Continuous video feeds from cameras, recording holistic measurements of animal behaviors.Advanced computational resources, which have generated 21 petabytes of proprietary high-dimensional data.ADMET (absorption, distribution, metabolism, excretion, and toxicology) data.This creates unique (and massive) datasets at all levels of the “multiomics” biosciences, including proteomics (protein levels), transcriptomics (mRNA levels), phenomics (cellular morphology), ADMET and “in-vivonomics” (animal behaviors). The company is also looking to add metabolomics and genomics to its datasets in the future.(you can read more about why multiomics matters in “Multiomics Are The Next Step In Biotechnology”).So while Exscientia started by studying biological mechanisms and designing a drug for it, Recursion instead built from scratch a massive database of standardized and replicated biological research.Recursion also acquired in May 2023 the drug chemistry-focused preclinical startups, Cyclica and Valance, for a total of $87.5M.They also own one of the world's fastest supercomputers to train their LLMs and AIs for drug discovery